Now reviewing cases nationwide involving Ozempic vision loss, Wegovy vision loss, and NAION linked to semaglutide.
If you or a loved one developed sudden or permanent vision loss after taking Ozempic, Wegovy, Mounjaro, Zepbound, or Rybelsus, you may qualify to file a GLP-1 lawsuit and pursue financial compensation.
A growing body of medical evidence suggests the answer may be yes—under certain conditions.
Recent studies, adverse event data, and ongoing litigation indicate a potential connection between ozempic and vision loss, particularly a condition known as:
NAION (non-arteritic anterior ischemic optic neuropathy) is a serious eye condition caused by reduced blood flow to the optic nerve.
When this occurs:
There is currently no effective treatment or cure for NAION.
Key findings include:
Despite sharing the same active ingredient as Ozempic, Wegovy (higher-dose semaglutide) has been linked to:
This has led to a surge in lawsuits against Wegovy.
If you or a loved one has been injured due to the use of Ozempic, Wegovy, Rybelsus or any other brand name weight loss drugs, don’t wait to seek legal help.
Contact Salenger, Sack, Kimmel & Bavaro today for a FREE consultation.
Call (800) 675-8556 or contact us online to get started.
As of May 2026, more than 4,400 lawsuits involving GLP-1 weight loss and diabetes medications are pending in federal court against manufacturers Novo Nordisk and Eli Lilly. The litigation centers on allegations that drugs such as Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus caused serious side effects including gastroparesis, bowel obstruction, and vision loss linked to NAION (non-arteritic anterior ischemic optic neuropathy).
Plaintiffs allege the manufacturers failed to adequately warn patients and healthcare providers about the potential risks associated with these medications. Both Novo Nordisk and Eli Lilly continue to deny liability and are actively contesting the claims.
A separate multidistrict litigation (MDL) focused on GLP-1-related vision loss and NAION claims was established in late 2025 and early 2026. The litigation involves allegations that semaglutide and tirzepatide medications may increase the risk of sudden, permanent vision impairment.
A major “Science Day” is scheduled for June 2026, where experts will present medical and scientific evidence to help educate the court about the alleged connection between GLP-1 drugs and NAION.
At this stage, no global settlement agreements have been reached.
Most legal analysts do not expect significant settlement discussions until after initial bellwether trials begin in 2026 or 2027, when juries will evaluate liability and damages in representative cases.
The growing popularity of GLP-1 drugs has also triggered increased regulatory scrutiny and related legal actions nationwide.
The FDA continues targeting companies selling unauthorized or compounded GLP-1 medications and has issued warnings regarding misleading marketing and non-approved formulations.
States have begun pursuing enforcement actions against unauthorized sellers of compounded or counterfeit GLP-1 drugs. In 2026, Connecticut reached a settlement with an international platform accused of selling unapproved “bootleg” GLP-1 medications.
In May 2026, a Washington state appeals court ruled that insurance providers cannot impose blanket exclusions on GLP-1 medications prescribed for weight loss purposes, marking a significant legal development for patient access.
Beginning July 1, 2026, Medicare is expected to implement a program capping certain GLP-1 prescription costs at $50 per month for eligible beneficiaries. Increased access to these medications may further increase public scrutiny and litigation attention surrounding their alleged risks.
Plaintiffs in ozempic lawsuits and wegovy class action lawsuits generally allege:
Many cases involve individuals who took the medication as prescribed and still developed NAION.
You may be eligible to file a weight loss drug lawsuit if:
To pursue an ozempic blindness lawsuit or wegovy lawsuit, you will need:
While ozempic lawsuit settlement amounts are still developing, compensation in similar pharmaceutical cases has included:
Settlement values will depend on severity of injury, documentation, and long-term impact.
Time is limited. Most states have a 2-3 year statute of limitations from the date the injury occurred—or the date you discovered the link to your medication. In New York, the deadline is typically three years, but certain exceptions may apply.
We strongly encourage you to act now to protect your right to sue.
With over four decades of experience in mass tort and product liability litigation, our firm is uniquely positioned to:
Fight back against major pharmaceutical companies
Provide personalized legal support at every step
Work on a contingency-fee basis — you pay nothing unless we win
Partner with renowned medical experts to strengthen your case
If you suffered NAION, blurry vision, or blindness after using Ozempic, Wegovy, Rybelsus, Mounjaro, Victoza, or Saxenda, we’re here to help.
📞 Call 800-675-8556 for a free case evaluation
🖊 Or complete our confidential contact form today.